BDNF and early-onset autosomal dominant Alzheimer disease: A clinical trial (Phase 1) of gene therapy utilizing AAV2-BDNF (encoding brain-derived neurotrophic factor) to address early Alzheimer’s disease (AD) and mild cognitive impairment in 12 participants is currently ongoing.